Drug Utilization Study of Vancomycin in a Tertiary Hospital
https://doi.org/10.33860/jik.v19i1.2026
Keywords:
Drug Utilization Study, Vancomycin, Tertiary Hospital, IndonesiaAbstract
Vancomycin possesses not only a narrow therapeutic range but also nephrotoxic effects, thus requiring intensive monitoring. This study aims to analyze the vancomycin use among the inpatients of a referral in Indonesia. This retrospective cross-sectional research collected a two-year data from medical records. The research involved all the patients who met the inclusion criteria. The majority of the 90 patients receiving vancomycin were men with the most age range of 18-60 years. The dominant indication of vancomycin use was sepsis typically caused by methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus haemolyticus. Meanwhile, the vancomycin dosing for the 1-<18 age range was mostly based on actual body weight, whereas that for other age categories took into account renal function. The effectiveness of vancomycin based on White Blood Cells and neutrophils was shown in 34.88% of patients examined for both parameters. In addition, 6.25% of the patients given a platelet count experienced suspected vancomycin-induced thrombocytopenia. No incidence of vancomycin-induced neutropenia and nephrotoxicity was found. Given that the risk of nephrotoxicity and the effectiveness of vancomycin are influenced by the steady-state concentrations and the area under the curve, this study recommends hospitals in Indonesia to provide Therapeutic Drug Monitoring (TDM) services.
References
Erikawati D, Santosaningsih D, Santoso S. Tingginya Prevalensi MRSA pada Isolat Klinik Periode 2010- 2014 di RSUD Dr. Saiful Anwar Malang, Indonesia. Jurnal Kedokteran Brawijaya. 2016 Aug 29;149–56.
Syahniar R, Rayhana, Kharisma DS, Khatam M, Duarsa DBB. Methicillin-Resistant Staphylococcus aureus among Clinical Isolates in Indonesia: A Systematic Review. Biomedical and Pharmacology Journal. 2020 Dec 30;13(4):1871–8.
Santosaningsih D, Santoso S, Budayanti NS, Kuntaman K, Lestari ES, Farida H, et al. Epidemiology of Staphylococcus aureus Harboring the mecA or Panton-Valentine Leukocidin Genes in Hospitals in Java and Bali, Indonesia. The American Journal of Tropical Medicine and Hygiene. 2014 Apr 2;90(4):728–34.
Wilson HJ, Khokhar F, Enoch DA, Brown NM, Ahluwalia J, Dougan G, et al. Point-prevalence survey of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci in adult inpatients in a university teaching hospital in the UK. Journal of Hospital Infection. 2018 Sep 1;100(1):35–9.
Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016 Jun;7(3):136–47.
Kan WC, Chen YC, Wu VC, Shiao CC. Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application. Int J Mol Sci. 2022 Feb 12;23(4):2052.
Humphrey C, Veve MP, Walker B, Shorman MA. Long-term vancomycin use had low risk of ototoxicity. PLOS ONE. 2019 Nov 6;14(11):e0224561.
Nuryah A, Yuniarti N, Puspitasari I. Prevalensi dan Evaluasi Kesesuaian Penggunaan Antibiotik pada Pasien dengan Infeksi Methicillin Resistant Staphylococcus Aureus di RSUP Dr. Soeradji Tirtonegoro Klaten. Majalah Farmaseutik. 2019 Sep 2;15(2):123–9.
Suardi M, Sofjan M, Raveinal R. Kesesuaian Dosis Vankomisin pada Pasien Penyakit Ginjal Kronik Stadium 3 dan 4 di Bangsal Penyakit Dalam RSUP Dr. M. Djamil Padang. Jurnal Sains Farmasi & Klinis. 2016 Dec 28;3(1):64–71.
Mahmoodian A, Abbasi S, Farsaei S. A new approach to Vancomycin utilization evaluation: A cross-sectional study in intensive care unit. J Res Pharm Pract. 2016;5(4):279–84.
Kabbara WK, El-Khoury G, Chamas NR. Prospective evaluation of vancomycin therapeutic usage and trough levels monitoring. The Journal of Infection in Developing Countries. 2018 Nov 30;12(11):978–84.
Salih TAM, Yousef BA, Salih MAM, Eltom KS. Drug Utilization Evaluation of Vancomycin among Patients in Jafar Ibn Auf Pediatric Hospital, 2018. F1000Res. 2021 Nov 12;8:1708.
Tang J, Hu J, Kang L, Deng Z, Wu J, Pan J. The use of vancomycin in the treatment of adult patients with methicillin-resistant Staphylococcus aureus (MRSA) infection: a survey in a tertiary hospital in China. Int J Clin Exp Med. 2015 Oct 15;8(10):19436–41.
Ruggieri A, Anticoli S, D’Ambrosio A, Giordani L, Viora M. The influence of sex and gender on immunity, infection and vaccination. Ann Ist Super Sanita. 2016 Jun;52(2):198–204.
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016 Oct;16(10):626–38.
Strich JR, Heil EL, Masur H. Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance. The Journal of Infectious Diseases. 2020 Jul 21;222(Supplement_2):S119–31.
Choo EJ, Chambers HF. Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Infect Chemother. 2016 Dec;48(4):267–73.
Zhang G, Zhang N, Xu J, Yang T, Yin H, Cai Y. Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. International Journal of Antimicrobial Agents. 2023 Oct 1;62(4):106946.
Haseeb A, Alqurashi MK, Althaqafi AS, Alsharif JM, Faidah HS, Bushyah M, et al. A Systematic Review on Clinical Safety and Efficacy of Vancomycin Loading Dose in Critically Ill Patients. Antibiotics. 2022 Mar 18;11(3):409.
Cong Y, Yang S, Rao X. Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. Journal of Advanced Research. 2020 Jan 1;21:169–76.
Boyce JM, Pop OF, Abreu-Lanfranco O, Hung WY, Fisher A, Karjoo A, et al. A Trial of Discontinuation of Empiric Vancomycin Therapy in Patients with Suspected Methicillin-Resistant Staphylococcus aureus Health Care-Associated Pneumonia. Antimicrob Agents Chemother. 2013 Mar;57(3):1163–8.
Reveles KR, Mortensen EM, Attridge RT, Frei CR. Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia. BMC Res Notes. 2015 Sep 17;8:450.
Ministry of Health of the Republic of Indonesia. Formularium Nasional (National Formulary) [Internet]. Ministry of Health of the Republic of Indonesia; 2021. Available from: http://farmalkes.kemkes.go.id/unduh/kmk-no-hk-01-07-menkes-350-2020-ttg-formularium-nasional/
F.R. Bruniera, F. M. Ferreira, L.R.M. SAVIOLLI, F.L.A. Fonseca, V.B. Campos Junqueira, Bacci MR, et al. The use of vancomycin with its therapeutic and adverse effects: a review [Internet]. European Review. 2015 [cited 2018 Feb 15]. Available from: http://www.europeanreview.org/article/8585
Budayanti NS, Aisyah DN, Fatmawati NND, Tarini NMA, Kozlakidis Z, Adisasmito W. Identification and Distribution of Pathogens in a Major Tertiary Hospital of Indonesia. Front Public Health. 2020 Jan 31;7:395.
McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, et al. Comparative Effectiveness of Beta-Lactams Versus Vancomycin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections Among 122 Hospitals. Clin Infect Dis. 2015 Aug 1;61(3):361–7.
Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012 Sep 1;68(9):1243–55.
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020 May 19;77(11):835–64.
Smit C, Goulooze SC, Brüggemann RJM, Sherwin CM, Knibbe CAJ. Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years. AAPS J. 2021 Apr 11;23(3):53.
Khare M, Azim A, Kneese G, Haag M, Weinstein K, Rhee KE, et al. Vancomycin Dosing in Children With Overweight or Obesity: A Systematic Review and Meta-analysis. Hosp Pediatr. 2020 Apr;10(4):359–68.
Woldu H, Guglielmo BJ. Incidence and Risk Factors for Vancomycin Nephrotoxicity in Acutely Ill Pediatric Patients: Journal of Pharmacy Technology [Internet]. 2017 Dec 10 [cited 2018 Sep 11]; Available from: http://journals.sagepub.com/doi/abs/10.1177/8755122517747088
Gu Q, Jones N, Drennan P, Peto TE, Walker AS, Eyre DW. Assessment of an institutional guideline for vancomycin dosing and identification of predictive factors associated with dose and drug trough levels. Journal of Infection. 2022 Oct 1;85(4):382–9.
Shahrami B, Najmeddin F, Mousavi S, Ahmadi A, Rouini MR, Sadeghi K, et al. Achievement of Vancomycin Therapeutic Goals in Critically Ill Patients: Early Individualization May Be Beneficial. Critical Care Research and Practice. 2016 Mar 17;2016:e1245815.
Hodiamont CJ, Juffermans NP, Berends SE, van Vessem DJ, Hakkens N, Mathôt RAA, et al. Impact of a vancomycin loading dose on the achievement of target vancomycin exposure in the first 24 h and on the accompanying risk of nephrotoxicity in critically ill patients. Journal of Antimicrobial Chemotherapy. 2021 Nov 1;76(11):2941–9.
Heffernan AJ, Germano A, Sime FB, Roberts JA, Kimura E. Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient? Eur J Clin Pharmacol. 2019 Sep 1;75(9):1219–26.
Katip W, Jaruratanasirikul S, Pattharachayakul S, Wongpoowarak W, Jitsurong A, Lucksiri A. The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock. IDR. 2016 Nov 22;9:253–60.
Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S, et al. Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 2022 Feb 23;14(3):489.
Flannery AH, Wallace KL, Rhudy CN, Olmsted AS, Minrath RC, Pope SM, et al. Efficacy and safety of vancomycin loading doses in critically ill patients with methicillin-resistant Staphylococcus aureus infection. Therapeutic Advances in Infection. 2021 Jan 1;8:20499361211005965.
Al Sulaiman K, Alshaya A, Aljuhani O, Alsaeed A, Alshehri N, Vishwakarma R, et al. The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: A retrospective cohort study. BMC Infectious Diseases. 2021 Nov 24;21(1):1182.
Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-39.
Vandecasteele SJ, De Vriese AS, Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. Journal of Antimicrobial Chemotherapy. 2013 Apr 1;68(4):743–8.
Lewis SJ, Nolin TD. New Vancomycin Dosing Guidelines for Hemodialysis Patients: Rationale, Caveats, and Limitations. Kidney360. 2021 Aug 26;2(8):1313–5.
Ponce D, Zamoner W, Freitas FM, Balbi A, Awdishu L. Vancomycin Removal During High-Volume Peritoneal Dialysis in Acute Kidney Injury Patients: A Prospective Cohort Clinical Study. Kidney Int Rep. 2018 Sep 27;4(1):112–8.
Lam E, Lien YT (Kayla), Kraft WK, Piraino B, Vozmediano V, Schmidt S, et al. Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy. Perit Dial Int. 2020 Jul 1;40(4):384–93.
Yamanouchi J, Hato T, Shiraishi S, Takeuchi K, Yakushijin Y, Yasukawa M. Vancomycin-induced Immune Thrombocytopenia Proven by the Detection of Vancomycin-dependent Anti-platelet Antibody with Flow Cytometry. Intern Med. 2016 Oct 15;55(20):3035–8.
Abdalhadi H, Fahmawi Y, Das A, Fouty B. Life-Threatening Intrapulmonary Hemorrhage due to Vancomycin-Induced Thrombocytopenia: A Case Report. Case Reports in Critical Care. 2020 Sep 30;2020:e8890335.
Guleng SR, Wu RH, Guo XB. Vancomycin-induced thrombocytopenia in endocarditis: A case report and review of literature. World Journal of Clinical Cases. 2021 Mar 6;9(7):1696–704.
Kalra K, Mittal HG, Maria A. Vancomycin-induced thrombocytopenia in a newborn. Drug Metabolism and Personalized Therapy. 2016 Dec 1;31(4):235–7.
Savage-Elliott I, Wu VJ, Sanchez FL. Drug-Induced Thrombocytopenia Secondary to Commonly Used Antibiotics in Total Joint Arthroplasty. Arthroplasty Today. 2020 Jun 1;6(2):137–40.
Shah RA, Musthaq A, Khardori N. Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report. J Med Case Reports. 2009 Dec;3(1):1–4.
HT. Nguyen, T. Pham, HT. Bui. Prevalence and related factors for injectable vancomycin or teicoplanin-associated thrombocytopenia in a Vietnamese hospital. 4. 2015;42:Mahidol University Journal of Pharmaceutical Sciences.
Danieletto CF, Ferreira GZ, Farah GJ, Cuman RKN. Vancomycin-induced thrombocytopenia: a rare adverse effect in a patient -submitted to bone graft in the jaw. Spec Care Dentist. 2017 Jan;37(1):38–42.
Mohammadi M, Jahangard-Rafsanjani Z, Sarayani A, Hadjibabaei M, Taghizadeh-Ghehi M. Vancomycin-Induced Thrombocytopenia: A Narrative Review. Drug Saf. 2017 Jan;40(1):49–59.
Tongsai S, Koomanachai P. The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Res Notes. 2016 Sep 29;9:455.
Filippone EJ, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin. Clinical Pharmacology and Therapeutics. 2017 Sep;102(3):459.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with Poltekita : Jurnal Ilmu Kesehatan agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
This work is licensed under a Creative Commons Attribution-ShareAlike 2.0 Generic License.
Poltekita : Jurnal Ilmu Kesehatan is licensed under a Creative Commons Attribution-Share Alike 4.0 International License
You are free to:
- Share, copy and redistribute the material in any medium or format
- Adapt, remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
